Cogent Biosciences (COGT) Stock Forecast & Price Target

Compare

599 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

COGT Analyst Ratings

Strong Buy

9 Buy

3 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Cogent

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

COGT Stock 12 Month Forecast

Average Price Target

$19.64

▲(57.75%Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $19.64 with a high forecast of $29.00 and a low forecast of $9.00. The average price target represents a 57.75% change from the last price of $12.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","17":"$17","30":"$30","10.5":"$10.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10.5,17,23.5,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.22,8.895384615384614,10.57076923076923,12.246153846153845,13.92153846153846,15.596923076923076,17.27230769230769,18.947692307692307,20.623076923076923,22.298461538461538,23.973846153846154,25.64923076923077,27.324615384615385,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.22,8.175384615384615,9.13076923076923,10.086153846153845,11.041538461538462,11.996923076923078,12.952307692307691,13.907692307692308,14.863076923076925,15.818461538461538,16.773846153846154,17.72923076923077,18.684615384615384,{"y":19.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.22,7.356923076923077,7.493846153846154,7.63076923076923,7.7676923076923075,7.904615384615385,8.041538461538462,8.178461538461539,8.315384615384616,8.452307692307691,8.589230769230769,8.726153846153846,8.863076923076923,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$29.00

Average Price Target$19.64

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David LebowitzCiti

Citi

$15→$22

Buy

76.71%

Upside

Reiterated

07/21/25

Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences

Andrew BerensLeerink Partners

Leerink Partners

$18

Buy

44.58%

Upside

Reiterated

07/14/25

Cogent Biosciences: Buy Rating Affirmed Amid Promising Trials and Strategic Advantages

Sam SlutskyLifeSci Capital

LifeSci Capital

$20

Buy

60.64%

Upside

Reiterated

07/12/25

Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)

Anupam RamaJ.P. Morgan

J.P. Morgan

$25→$29

Buy

132.93%

Upside

Reiterated

07/10/25

Promising Outlook for Cogent Biosciences: Bezuclastinib's Potential in Systemic Mastocytosis and Beyond

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

07/08/25

Needham Reaffirms Their Hold Rating on Cogent Biosciences (COGT)

Colleen M. KusyRobert W. Baird

Robert W. Baird

$7→$9

Hold

-27.71%

Downside

Reiterated

07/08/25

Cogent Biosciences price target raised to $9 from $7 at BairdCogent Biosciences price target raised to $9 from $7 at Baird

Louise ChenScotiabank

Scotiabank

$17

Buy

36.55%

Upside

Reiterated

07/08/25

Scotiabank Sticks to Its Buy Rating for Cogent Biosciences (COGT)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$12→$22

Buy

76.71%

Upside

Reiterated

07/08/25

Cogent Biosciences price target raised to $22 from $12 at H.C. WainwrightCogent Biosciences price target raised to $22 from $12 at H.C. Wainwright

Kelly ShiJefferies

Jefferies

$23→$28

Buy

124.90%

Upside

Reiterated

07/07/25

Cogent Biosciences price target raised at Jefferies after 'home run' dataCogent Biosciences price target raised at Jefferies after 'home run' data

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$17

Buy

36.55%

Upside

Reiterated

07/07/25

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Unknown AnalystWedbush

Not Ranked

Wedbush

$10

Hold

-19.68%

Downside

Reiterated

06/30/25

Cogent Biosciences (COGT) Receives a Hold from Wedbush

Allison BratzelPiper Sandler

Piper Sandler

$24

Buy

92.77%

Upside

Reiterated

06/25/25

Piper Sandler Keeps Their Buy Rating on Cogent Biosciences (COGT)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David LebowitzCiti

Citi

$15→$22

Buy

76.71%

Upside

Reiterated

07/21/25

Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences

Andrew BerensLeerink Partners

Leerink Partners

$18

Buy

44.58%

Upside

Reiterated

07/14/25

Cogent Biosciences: Buy Rating Affirmed Amid Promising Trials and Strategic Advantages

Sam SlutskyLifeSci Capital

LifeSci Capital

$20

Buy

60.64%

Upside

Reiterated

07/12/25

Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)

Anupam RamaJ.P. Morgan

J.P. Morgan

$25→$29

Buy

132.93%

Upside

Reiterated

07/10/25

Promising Outlook for Cogent Biosciences: Bezuclastinib's Potential in Systemic Mastocytosis and Beyond

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

07/08/25

Needham Reaffirms Their Hold Rating on Cogent Biosciences (COGT)

Colleen M. KusyRobert W. Baird

Robert W. Baird

$7→$9

Hold

-27.71%

Downside

Reiterated

07/08/25

Cogent Biosciences price target raised to $9 from $7 at BairdCogent Biosciences price target raised to $9 from $7 at Baird

Louise ChenScotiabank

Scotiabank

$17

Buy

36.55%

Upside

Reiterated

07/08/25

Scotiabank Sticks to Its Buy Rating for Cogent Biosciences (COGT)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$12→$22

Buy

76.71%

Upside

Reiterated

07/08/25

Cogent Biosciences price target raised to $22 from $12 at H.C. WainwrightCogent Biosciences price target raised to $22 from $12 at H.C. Wainwright

Kelly ShiJefferies

Jefferies

$23→$28

Buy

124.90%

Upside

Reiterated

07/07/25

Cogent Biosciences price target raised at Jefferies after 'home run' dataCogent Biosciences price target raised at Jefferies after 'home run' data

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$17

Buy

36.55%

Upside

Reiterated

07/07/25

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Unknown AnalystWedbush

Not Ranked

Wedbush

$10

Hold

-19.68%

Downside

Reiterated

06/30/25

Cogent Biosciences (COGT) Receives a Hold from Wedbush

Allison BratzelPiper Sandler

Piper Sandler

$24

Buy

92.77%

Upside

Reiterated

06/25/25

Piper Sandler Keeps Their Buy Rating on Cogent Biosciences (COGT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cogent Biosciences

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+10.51%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +10.51% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+17.45%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +17.45% per trade.

1 Year

Andrew BerensLeerink Partners

Success Rate

8/11 ratings generated profit

Average Return

+30.83%

reiterated a buy rating 10 days ago

Copying Andrew Berens's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +30.83% per trade.

2 Years

xxx

Success Rate

14/16 ratings generated profit

Average Return

+43.59%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +43.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COGT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, COGT has received 21 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. COGT average Analyst price target in the past 3 months is 19.64.

Each month's total comprises the sum of three months' worth of ratings.

COGT Financial Forecast

COGT Earnings Forecast

Next quarter’s earnings estimate for COGT is -$0.59 with a range of -$0.66 to -$0.46. The previous quarter’s EPS was -$0.64. COGT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.18% of the time in the same period. In the last calendar year COGT has Preformed in-line its overall industry.

COGT Sales Forecast

Next quarter’s sales forecast for COGT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COGT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 71.19% of the time in the same period. In the last calendar year COGT has Preformed in-line its overall industry.

COGT Stock Forecast FAQ

What is COGT’s average 12-month price target, according to analysts?

Based on analyst ratings, Cogent Biosciences’s 12-month average price target is 19.64.

What is COGT’s upside potential, based on the analysts’ average price target?

Cogent Biosciences has 57.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COGT a Buy, Sell or Hold?

Cogent Biosciences has a consensus rating of Strong Buy which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.

What is Cogent Biosciences’s price target?

The average price target for Cogent Biosciences is 19.64. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $9.00. The average price target represents 57.75% Increase from the current price of $12.45.

What do analysts say about Cogent Biosciences?

Cogent Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of COGT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cogent Biosciences (COGT) Stock Forecast & Price Target

COGT Analyst Ratings

COGT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cogent Biosciences

COGT Analyst Recommendation Trends

COGT Financial Forecast

COGT Earnings Forecast

COGT Sales Forecast

COGT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts